Attached files
| file | filename |
|---|---|
| EXCEL - IDEA: XBRL DOCUMENT - AEOLUS PHARMACEUTICALS, INC. | Financial_Report.xls |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.20549
____________
FORM 10-K/A
(Amendment No. 1)
____________
(MARK ONE)
ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended September 30, 2014
OR
¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ____________ to__________
Commission File Number 0-50481
____________
AEOLUS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
____________
|
Delaware
(State or other jurisdiction of
incorporation or organization)
|
56-1953785
(I.R.S. Employer
Identification No.)
|
|
26361 Crown Valley Parkway, Suite 150
Mission Viejo, California
(Address of principal executive offices)
|
92691
(Zip Code)
|
|
Registrant’s telephone number, including area code: 949-481-9825
|
|
|
Securities registered pursuant to Section 12(b) of the Act: None
|
|
|
Securities registered pursuant to Section 12(g) of the Act:
Common Stock, $.01 par value per share
(Title of class)
|
|
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ¨No ý
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ¨No ý
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ýNo ¨
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ýNo ¨
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ¨ Accelerated filer ¨ Non-accelerated filer ¨ Smaller reporting company ý
(Do not check if a smaller reporting company)
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes ¨No ý
The aggregate market value of the voting common stock held by non-affiliates of the registrant based upon the average of the bid and asked price on the OTC Bulletin Board as of March 31, 2014, the last business day of the registrant’s most recently completed second fiscal quarter, was approximately $33,637,517. Shares of common stock held by each executive officer and director and by each other stockholder who owned 10% or more of the outstanding common stock as of such date have been excluded in that such stockholder might be deemed to be an affiliate of the registrant. This determination of affiliate status might not be conclusive for other purposes.
As of December 22, 2014, the registrant had 135,850,068 outstanding shares of common stock.
EXPLANATORY NOTE
This Amendment No. 1 on Form 10-K/A (the “Amendment”), amends our Annual Report on Form 10-K for the fiscal year ended September 30, 2014, originally filed on December 22, 2014 (the “Original Filing”). The sole purpose of the Amendment is to furnish Exhibit 101 to the Original Filing which contains the XBRL (eXtensible Business Reporting Language) Interactive Data Files for the financial statements and notes included in the Original Filing. Except as described above, no other changes have been made to the Original Filing.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| AEOLUS PHARMACEUTICALS, INC. | ||
| By: /s/ John L. McManus | ||
| John L. McManus | ||
| President and Chief Executive Officer | ||
|
Date: February 13, 2015
|
||
|
Exhibit
Number
|
Description of Document
|
Filed
Herewith
|
|
101.INS†
|
XBRL Instance Document
|
X
|
||
|
101.SCH†
|
XBRL Taxonomy Extension Schema Document
|
X
|
||
|
101.CAL†
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
X
|
||
|
101.DEF†
|
XBRL Taxonomy Extension Definition Linkbase Document
|
X
|
||
|
101.LAB†
|
XBRL Taxonomy Extension Label Linkbase Document
|
X
|
||
|
101.PRE†
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
X |
† Attached as Exhibit 101 to this report are documents formatted in XBRL (Extensible Business Reporting Language). Users of this data are advised that, pursuant to Rule 406T of Regulation S-T, the interactive data file is deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is otherwise not subject to liability under these sections.